TLR4 and Parkinson disease: FMT improved physical impairment in PD mice, lowered fecal SCFAs, reduced GM dysbiosis, boosted striatal DA and 5-HT content, reduced microglia and astrocyte activation in the substantia nigra, and decreased expression of TLR4/TNF-α signaling pathway components in the gut and brain.